This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. Branded drugs, developed through extensive research and clinical trials, often enjoy patent protection for a limited period.
One is at a healthcare provider level, where the latest advances in genetic testing and biomarker measurement have the potential to boost the early detection of conditions and hone decision-making around the most effective treatments. Assessing opportunities in the context of brand strategy. Breaking down the opportunities.
Introduction In todays digital-first world, content marketing campaigns are no longer optional for pharmaceutical brands. Imagine content marketing as the heartbeat of a pharma brands digital presence. Instead of traditional promotional tactics, pharma brands can use educational content to build credibility.
In the life sciences industry, where company names derived from “biology” or “genetics” are a dime a dozen, it helps to have a brand that stands out. Pretzel Therapeutics is one of this year’s more creative gambits, launching Monday with $72.5 Continue to STAT+ to read the full story…
Eli Lilly is investing $700M into genetic medicine, announcing plans to establish a Boston research center, and with the acquisition of Prevail Therapeutics in late 2020, Lilly secured access to two gene therapies that had already advanced into human testing — with one targeting Parkinson’s disease and the other, dementia.
Pharma companies are always talking about moving ‘beyond the pill’, and Pfizer’s new brand identity embodies that – it’s decades old pill-like logo has been replaced with a DNA double helix that it says reflects its commitment to breakthrough science. Encoded within a successful emblem is a company’s DNA – its history, its future.
“We also benefit from having cGMP manufacturing capabilities in compliance with global regulatory requirements, a strong heritage from our mother company’s brand, a proven track record of reliable and secure supply, and a new partner that is probably the best player in the market within enzyme diversity.
The collection was developed through traditional breeding methods, without genetically modified organisms (GMOs) and each flavor took 20 years to perfect and commercialize. In this episode of the Xtalks Food Podcast, Sydney talks about Driscoll’s curated collection of strawberries, including Rose Berries, Sweetest Batch and Tropical Bliss.
The production of commercial dose non-sterile products such as tablets, capsules, ointments, creams, and powders is rising due to their growing global demand, attributed to increasing demand for anti-ageing products, hereditary factors, genetic mutations, exposure to harmful radiation, and rising geriatric population.
Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., Here are 5 considerations when developing a communications strategy for a novel genetic medicine. #1. Genetic literacy among clinicians may not be as high as you think. Creating a simple narrative is, of course, not simple.
Conscious Greens is the first offering from Pairwise’s new brand, Conscious Foods. Pairwise teamed up with Performance Food Group (PFG) to co-brand its Purple Power Baby Greens Blend under PFG’s Peak Fresh Produce premium brand. Paul region, St. Louis and Springfield, Massachusetts.
So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). Ex vivo (where cells are genetically modified outside the body) cell and gene therapies have generated considerable excitement on their potential to cure previously incurable diseases.
This strategic move transformed Actavis into one of the largest pharma companies globally, with a strong presence across branded, generic and over-the-counter (OTC) medicines. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.
One group excelling in this space is the Genetic Alliance. Their work ranges from developing new services in partnership with the National Health Service (NHS) to working with the All Party Parliamentary Group on Rare, Genetic and Undiagnosed Conditions, and the Department of Health on the UK Strategy for Rare Diseases.
The Paleo certification program is based on the organization’s principle of encouraging the avoidance of dairy products, genetically modified organisms (GMO’s), grains, highly processed foods and legumes, among other foods.
Ipsen’s consumer health range includes brands like diarrhoea remedy Smecta, Forlax for constipation and Ginkgo biloba supplement Tanakan, which recorded revenues of €226 million in 2021, up 8%. Ipsen’s specialty pharma business grew almost 13% to €2.6 billion last year. billion takeover of Clementia Pharma in 2019.
By fostering a sense of community, addressing pain points and sharing impactful stories, podcasts can strengthen ties with an audience, drive brand loyalty and help life science organizations position themselves for long-term success in an increasingly competitive landscape. Have questions?
The company’s major products include CAM2038 to treat chronic pain; CAM2029 to treat acromegaly, GEP-NET and PLD; CAM4072 to treat genetic obesity disorders; CAM2032 to treat Prostate cancer; CAM2043 to treat pulmonary arterial hypertension and raynaud’s phenomenon; CAM4071 to treat endocrine disorders; buvidal drug candidates.
The company’s major products include CAM2038 to treat chronic pain; CAM2029 to treat acromegaly, GEP-NET and PLD; CAM4072 to treat genetic obesity disorders; CAM2032 to treat Prostate cancer; CAM2043 to treat pulmonary arterial hypertension and raynaud’s phenomenon; CAM4071 to treat endocrine disorders; buvidal drug candidates.
The Kraft Heinz Company made waves in the food industry by introducing vegan hot dogs and sausages under its well-known Oscar Mayer brand. This significant move marks the brand’s first foray into the plant-based arena with its NotHotDogs and NotSausages.
PharmaTher also has an agreement in place with Case Western Reserve University to develop ketamine as a treatment for Rett syndrome, a rare genetic neurological disorder. The company now plans to move this approach into a Phase III trial. PharmaTher is not the only player in this space.
In 2025, pharmaceutical trends are redefining how brands connect with healthcare professionals (HCPs), patients, and stakeholders. Patients expect pharma brands to provide educational resources, medication support, and real-time interactions across apps, websites, and social media. How does this impact pharma marketing?
The reason for excluding this ingredient is that the company’s other products were not allowed to be sold in Europe or China because the heme comes from genetically modified soy. Major companies have already positioned their vegan chicken brands in the market, such as Simulate’s NUGGS, McDonald’s McPlant and Maple Leaf Foods’ Lightlife.
We understand the tau protein, that some people have inflammation in the brain or a genetic predisposition. Yet, risk factors such as an extensive family history of the disease or genetic markers are known long before patients hit that age. “If Donanemab was approved under the brand name Kisunla.
In other cases, rare CNS conditions may be passed on from one generation to the next without knowledge or understanding that the reason for suffering or death among previous generations was genetic in basis and therefore identifiable, and perhaps even treatable.
Ayesha obtained an MSc in Cancer & Genetics from McMaster University and a PhD in Medical Biophysics from the University of Toronto. Sustainability : Food packaging, waste and initiatives put forward by brands to reduce their environmental footprints. 3. A Podcast to Help Food Industry Professionals Stay Informed.
Genetic analysis of tumours can reveal mutations that are fuelling cancers growth, some of which can be targeted with treatment, they note. It was able to predict the efficacy of some established combination therapies for NSCLC, such as BRAF/MEK and EGFR/mTOR inhibitors, but also identified brand new recipes.
Approximately 85% of rare diseases are genetic, offering significant opportunities to develop better treatments as our understanding of the human genome improves 1. Concentrating on patient identification early in the clinical phases can drive brand loyalty and develop more effective tactics, to address unmet patient needs.
23andMe is best known for its saliva-based health and ancestry DNA testing targeted at consumers, but the company also uses its genetic database to look for new targets for drug development. That’s been achieved thanks to a group of 10 million people worldwide who have agreed to allow their genetic data to be used for research.
It is estimated that there are currently more than 7,000 orphan diseases, many of which are considered life-threatening and most of which have a genetic basis. Despite this high number, orphan diseases are rare by definition, affecting around one in 2,000 people as defined by the European Union.
billion for MedCo, clearly thinking it can succeed where its rivals have so far failed and build inclisiran into a blockbuster brand if it gets approved by the FDA, which is due to deliver a verdict sometime before the end of this year. Novartis paid a hefty $9.7
This research also shows the complex system that drives our health outcomes, including the environment, our genetics and our social circumstances. Personalisation : creating interventions based on individuals knowing their genetics, biology and psychology as well as their social and geographical environment.
The Medicines and Healthcare product Regulatory Agency (MHRA) has issued a positive opinion on tepotinib as a treatment for adult NSCLC patient whose tumours have METex14 skipping alterations, a form of genetic mutation that occurs in around 3% to 4% of NSCLC cases.
It’s the latest twist in the turbulent tale of the ultra-rare disease therapy – developed to treat genetic disorder fibrodysplasia ossificans progressiva (FOP) – which has seen progress to the US market held up by a series of clinical and regulatory obstacles.
Health Canada has given the drug a green light – under the Sohonos brand – to treat fibrodysplasia ossificans progressiva (FOP), making it the first treatment for the ultra-rare genetic disorder. agonist for both chronic use and flare-ups in FOP, a genetic disorder in which tendons and ligaments gradually become more bone-like.
Pfizer’s size, solid manufacturing capability and experience running large scale vaccine trials combined with BioNTech’s strong science created a synergistic effect that resulted in the first COVID-19 vaccine approved by the FDA for emergency use in December 2020, just 336 days after the genetic blueprint of the virus was published.
In Europe, the drug, branded Albrioza, was turned down by the European Medicines Agency (EMA), a decision that Amylyx appealed and lost in October 2023. Despite failing in ALS, Amylyx isn’t completely pulling the plug on AMX0035.
billion investment by the pharma group, earmarked for two brand new manufacturing facilities. They will be used to produce “active ingredients and new therapeutic modalities, such as genetic medicines,” said the company in a statement. Eli Lilly’s home state of Indiana is set to benefit from a massive $2.1
The name Zeneca was invented by a branding consultancy who had been instructed to find a name which was memorable, had no associations with other companies, nor was offensive in any language”. The profits from these products funded the development of new drugs, such as gastroesophageal treatment Losec and cardiovascular treatment Aptin.
What this looks like in our work: How does a brand compete for mindshare competition, where a patient may listen to their doctor for 10 minutes, but then spends hours scrolling social media for information that may be misinformation or disinformation? Content is the first contact with brands. Memorable Relevant Quotes.
Scientists are fighting back with multiple strategies, including vaccines, repurposed drugs developed for other diseases and brand-new therapies. SARS-CoV-2, the virus responsible for COVID-19, has wreaked havoc on health care systems, economies and everyday lives worldwide.
Genotoxicity involves damage to genetic material within cells, increasing cancer and inherited disease risks. Major producers, like Unilever’s Unox brand, which produces 16 million smoked sausages annually, will need to reformulate their products. The ban targets artificial smoke flavorings linked to genotoxicity concerns.
This underscores our business’ strong cash generation ability, our confidence in our fundamental growth driven by the 14 global brands, and our belief that the R&D strategy with ~40 new molecular entities in the pipeline, will deliver for the long term.” Reason for acquisition of its own shares.
The vaccine is branded as Nuvaxovid outside the US with approvals/authorizations in Canada, the EU, UK, Australia and South Korea. In a press release outlining the authorization, the FDA noted that the clinical trial for Novavax’s vaccine was conducted before the appearance of the omicron and delta variants.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content